Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[SponsorSearch] Agios Pharmaceuticals Inc
#
NCTID/Status
Study
Last Changed
1
NCT04164901
Not yet recruiting
Not yet recruiting
Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Conditions: Grade 2 Glioma; Residual Glioma; Recurrent Glioma
Intervention: AG-881, Matching Placebo
Conditions: Grade 2 Glioma; Residual Glioma; Recurrent Glioma
Intervention: AG-881, Matching Placebo
November 20, 2019
2
NCT04145128
Recruiting
Recruiting
A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
Conditions: Healthy Volunteers
Intervention: AG881
Conditions: Healthy Volunteers
Intervention: AG881
October 29, 2019
3
NCT04128787
Active, not recruiting
Active, not recruiting
A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881
Conditions: Healthy Volunteers
Intervention: AG881 Formulation 1, AG881 Formulation 2, Omeprazole
Conditions: Healthy Volunteers
Intervention: AG881 Formulation 1, AG881 Formulation 2, Omeprazole
December 3, 2019
4
NCT04015687
Completed
Completed
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
Conditions: Healthy Participants
Intervention: AG-881, Lamotrigine
Conditions: Healthy Participants
Intervention: AG-881, Lamotrigine
October 11, 2019
5
NCT03991312
Completed
Completed
Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants
Conditions: Healthy Volunteers
Intervention: Itraconazole, Rifampin, Mitapivat Sulfate
Conditions: Healthy Volunteers
Intervention: Itraconazole, Rifampin, Mitapivat Sulfate
October 22, 2019
6
NCT03960502
Completed
Completed
A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881
Conditions: Healthy Male Participants
Intervention: AG-881, [13C315N3]AG-881
Conditions: Healthy Male Participants
Intervention: AG-881, [13C315N3]AG-881
October 22, 2019
7
NCT03853798
Recruiting
Recruiting
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
Conditions: Pyruvate Kinase Deficiency
Intervention: AG-348
Conditions: Pyruvate Kinase Deficiency
Intervention: AG-348
November 20, 2019
8
NCT03834584
Recruiting
Recruiting
A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Conditions: Lymphoma
Intervention: AG-636
Conditions: Lymphoma
Intervention: AG-636
November 5, 2019
9
NCT03703505
Completed
Completed
A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348
Conditions: Healthy Volunteers
Intervention: AG-348, [13C6]AG-348
Conditions: Healthy Volunteers
Intervention: AG-348, [13C6]AG-348
October 10, 2018
10
NCT03692052
Recruiting
Recruiting
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
Conditions: Thalassemia
Intervention: AG-348
Conditions: Thalassemia
Intervention: AG-348
October 18, 2019
11
NCT03559699
Recruiting
Recruiting
A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
Conditions: Pyruvate Kinase Deficiency; Anemia, Hemolytic
Intervention: AG-348
Conditions: Pyruvate Kinase Deficiency; Anemia, Hemolytic
Intervention: AG-348
December 10, 2019
12
NCT03548220
Recruiting
Recruiting
A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
Conditions: Pyruvate Kinase Deficiency; Anemia, Hemolytic
Intervention: AG-348, Placebo
Conditions: Pyruvate Kinase Deficiency; Anemia, Hemolytic
Intervention: AG-348, Placebo
December 10, 2019
13
NCT03481738
Recruiting
Recruiting
Pyruvate Kinase Deficiency Global Longitudinal Registry
Conditions: Pyruvate Kinase Deficiency
Conditions: Pyruvate Kinase Deficiency
October 22, 2019
14
NCT03435250
Recruiting
Recruiting
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Conditions: Advanced Solid Tumors; Lymphoma
Intervention: AG-270, AG-270, AG-270, Docetaxel, Nab-paclitaxel, Gemcitabine
Conditions: Advanced Solid Tumors; Lymphoma
Intervention: AG-270, AG-270, AG-270, Docetaxel, Nab-paclitaxel, Gemcitabine
November 19, 2019
15
NCT03397329
Completed
Completed
Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults
Conditions: Healthy Volunteers
Intervention: AG-348 Sequence A, AG-348 Sequence B
Conditions: Healthy Volunteers
Intervention: AG-348 Sequence A, AG-348 Sequence B
January 10, 2018
16
NCT03361358
Recruiting
Recruiting
Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
Conditions: Advanced Solid Tumors; Lymphoma
Conditions: Advanced Solid Tumors; Lymphoma
November 19, 2019
17
NCT03343197
Active, not recruiting
Active, not recruiting
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Conditions: Glioma
Intervention: AG-120, AG881
Conditions: Glioma
Intervention: AG-120, AG881
October 25, 2019
18
NCT03282513
Completed
Completed
A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Conditions: Hepatic Impairment
Intervention: AG-120 (Ivosidenib)
Conditions: Hepatic Impairment
Intervention: AG-120 (Ivosidenib)
April 26, 2018
19
NCT03250598
Completed
Completed
Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin
Conditions: Healthy; Japanese; Non-Asian
Intervention: AG-348, AG-348, AG-348
Conditions: Healthy; Japanese; Non-Asian
Intervention: AG-348, AG-348, AG-348
October 17, 2017
20
NCT03245424
Approved for marketing
Approved for marketing
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
Conditions: Acute Myeloid Leukemia; Relapsed Adult AML; Relapsed Pediatric AML
Intervention: Ivosidenib (AG-120)
Conditions: Acute Myeloid Leukemia; Relapsed Adult AML; Relapsed Pediatric AML
Intervention: Ivosidenib (AG-120)
July 20, 2018
21
NCT03173248
Recruiting
Recruiting
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); Leukemia, Myeloid, Acute
Intervention: AG-120 (ivosidenib) With Azacitidine, Placebo With Azacitidine
Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); Leukemia, Myeloid, Acute
Intervention: AG-120 (ivosidenib) With Azacitidine, Placebo With Azacitidine
October 23, 2019
22
NCT03071770
Completed
Completed
Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects
Conditions: Healthy
Intervention: Ivosidenib (AG-120)
Conditions: Healthy
Intervention: Ivosidenib (AG-120)
January 9, 2018
23
NCT02989857
Active, not recruiting
Active, not recruiting
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Intervention: AG-120, AG-120 Matched Placebo
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Intervention: AG-120, AG-120 Matched Placebo
October 9, 2019
24
NCT02831972
Completed
Completed
Drug-Drug Interaction Study of AG120 in Healthy Subjects
Conditions: Healthy
Intervention: AG120, Itraconazole
Conditions: Healthy
Intervention: AG120, Itraconazole
June 26, 2017
25
NCT02632708
Active, not recruiting
Active, not recruiting
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); AML Arising From Antecedent Hematologic Disorder (AHD); AML Arising After Exposure to Genotoxic Injury
Intervention: AG-120, AG-221, Cytarabine, Daunorubicin, Idarubicin, Mitoxantrone, Etoposide
Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); AML Arising From Antecedent Hematologic Disorder (AHD); AML Arising After Exposure to Genotoxic Injury
Intervention: AG-120, AG-221, Cytarabine, Daunorubicin, Idarubicin, Mitoxantrone, Etoposide
October 23, 2019
26
NCT02630927
Terminated
Terminated
A Safety and Tolerability Study of AG-519 in Healthy Subjects
Conditions: Anemia
Intervention: AG-519, Placebo
Conditions: Anemia
Intervention: AG-519, Placebo
June 27, 2017
27
NCT02579707
Completed
Completed
November 28, 2016
28
NCT02492737
Completed
Completed
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome; Hematologic Malignancies
Intervention: AG881
Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome; Hematologic Malignancies
Intervention: AG881
March 6, 2019
29
NCT02489513
Completed
Completed
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120
Conditions: Healthy Volunteers
Intervention: [14C]-AG-120
Conditions: Healthy Volunteers
Intervention: [14C]-AG-120
December 11, 2015
30
NCT02481154
Active, not recruiting
Active, not recruiting
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Conditions: Glioma
Intervention: AG881
Conditions: Glioma
Intervention: AG881
October 17, 2019
31
NCT02476916
Active, not recruiting
Active, not recruiting
A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency
Conditions: Pyruvate Kinase Deficiency
Intervention: AG-348
Conditions: Pyruvate Kinase Deficiency
Intervention: AG-348
October 9, 2019
32
NCT02218346
Completed
Completed
Food Effect Study of AG-221 in Healthy Male Subjects
Conditions: Healthy Volunteers
Intervention: AG221
Conditions: Healthy Volunteers
Intervention: AG221
December 11, 2015
33
NCT02149966
Completed
Completed
A Phase I Study of AG-348 in Healthy Volunteers
Conditions: Healthy Volunteer
Intervention: AG-348, Placebo
Conditions: Healthy Volunteer
Intervention: AG-348, Placebo
November 7, 2014
34
NCT02108106
Completed
Completed
A Phase I Study of AG-348 in Healthy Volunteers
Conditions: Healthy Volunteer
Intervention: AG-348, Placebo
Conditions: Healthy Volunteer
Intervention: AG-348, Placebo
October 21, 2014
35
NCT02074839
Recruiting
Recruiting
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML); Untreated AML; Other IDH1-mutated Positive Hematologic Malignancies; Myelodysplastic Syndromes
Intervention: AG-120
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML); Untreated AML; Other IDH1-mutated Positive Hematologic Malignancies; Myelodysplastic Syndromes
Intervention: AG-120
November 22, 2019
36
NCT02073994
Active, not recruiting
Active, not recruiting
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Other Advanced Solid Tumors
Intervention: AG-120
Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Other Advanced Solid Tumors
Intervention: AG-120
November 19, 2019
37
NCT03564821
Recruiting
Recruiting
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Conditions: IDH1 Mutation Myeloid Neoplasms
Intervention: Ivosidenib
Conditions: IDH1 Mutation Myeloid Neoplasms
Intervention: Ivosidenib
November 24, 2019
38
NCT02053480
Active, not recruiting
Active, not recruiting
Pyruvate Kinase Deficiency Natural History Study
Conditions: Pyruvate Kinase Deficiency; Congenital Non-Spherocytic Hemolytic Anemia
Conditions: Pyruvate Kinase Deficiency; Congenital Non-Spherocytic Hemolytic Anemia
September 6, 2019
39
NCT01915498
Active, not recruiting
Active, not recruiting
Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Conditions: Hematologic Neoplasms
Intervention: AG-221
Conditions: Hematologic Neoplasms
Intervention: AG-221
October 20, 2019
40
NCT04056910
Not yet recruiting
Not yet recruiting
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Conditions: Advanced Solid Tumor; IDH1 Mutation; Glioma
Intervention: Ivosidenib And Nivolumab
Conditions: Advanced Solid Tumor; IDH1 Mutation; Glioma
Intervention: Ivosidenib And Nivolumab
November 4, 2019
Last Updated
The last updated date is the most recent date when changes to a clinical trial were
submitted to ClinicalTrials.gov. There is often a delay of a few days before the
updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted
to ClinicalTrials.gov. There is often a delay of a few days before the
trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Safety Issue
If selected, restricts search results to those studies which have
an outcome measure designated as a safety issue. Note that this is a
poor estimate of the safety of a treatment or intervention, but it is
all we have now.
Funded By
Studies are supported by one or more organizations called sponsors.
Support includes contributions of facilities, expertise, and/or financial resources.
All sponsors in the database have been assigned one of the following organization types:
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Study Phase
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Age Group
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Gender
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility
name (such as the Mayo Clinic), enter it as a location term. Not all studies
include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency,
or organization sponsoring the trial. In addition, clinical trials assigns a
unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit.
Use this box to search for a trial by NCT identifier or any other study
identification numbers.
Examples:
Examples:
NCT00001789
97-h-0197
ia0006
actg 076
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is
conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are
conducting or otherwise supporting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Outcome Measures
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Outcome measures are used to evaluate trial results. For example, an obesity treatment
might be evaluated by a measure of weight loss after 6 months. Measures can also be used
to quantify side effects, such as number of myocardial infarctions,
number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Interventions
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Conditions
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Study Type
There are three types of studies available in ClinicalTrials.gov:
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Observational:
Expanded Access:
Studies where individuals are assigned to receive specific interventions.
Participants may receive diagnostic, therapeutic or other types of interventions.
Assignment of the intervention may or may not be random.
Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention.
Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals.
Participants may receive diagnostic, therapeutic, or other interventions, but the investigator
does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who
are failing on currently available treatments for their condition and also are unable to
participate in ongoing clinical trials. Expanded Access records are used to register all
types of non-protocol access to experimental treatments, including protocol exception,
single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Study Results
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Search Terms
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies.
These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Advanced Search:
Many searches are a single term and can be performed with a few words in the
search box. But, sometimes you need more control. Click on the Advanced Search tab
(if starting a new search) or Refine Search tab (if modifying an existing search)
to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Recruitment:
Interventions:
Outcomes Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
Country/State:
Location Terms:
Gender:
Age Group:
Phase:
Funded By:
Safety Issue:
First Received:
Last Updated:
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Performs a general search in all sections of the study record, including title,
description, conditions, interventions, locations, etc. Terms in this field are
searched the same as Basic Search.
Recruitment:
Limits search results to studies that are open or closed. New volunteers may be
able to participate in open studies, but not closed studies.
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Study Results:Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Values are color coded (as shown) in the search results.
Limits search results based on whether the study has results or not:
Study Type:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov.
Only a few studies have results available.Studies With Results, or
Studies Without Results
Limits search results to any of the following study types:
Conditions:
Interventional,
Observational, or
Expanded Access
Observational, or
Expanded Access
Performs a search on fields describing the diseases or conditions being studied.
Interventions:
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Sponsor/Collaborators:
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor (Lead):
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Study IDs:
Performs a search on fields listing ID numbers.
Country/State:
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state (e.g., United States, Alabama).
Location Terms:
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic).
Not all studies include this level of detail, but if they do, this will find them.
Gender:
Limits search results to those studies that accept female or male participants.
Age Group:
Limits search results to those studies that include at least one of the specified age
ranges. More than one age group can be selected.
Phase:
Limits search results to studies that are labeled with at least one of the specified
phases. More than one Phase can be selected.
Funded By:
Limits search results to studies that have at least one sponsor of the specified types.
More than one sponsor type can be selected.
Safety Issue:
Limits search results to studies that have at least one outcome measure designated as a safety issue.
First Received:
Limits search results to studies that were received by clinical trials within a
specified date range. The "From" or "To" field can be left blank.
Last Updated:
Limits search results to studies that were modified within a
specified date range. The "From" or "To" field can be left blank.
Refine Search:
Searches display a list of studies found (List Results tab). If you are not content with
the search results, click on the Refine Search tab at the top of the list to modify your
search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
When you are done making changes, click Search to display the new results.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
For example:
prostate cancer AND radiation
heart disease AND stroke AND California
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Aspirin OR ibuprofen
heart disease OR heart attack
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.